DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

As the leader of Connecticut’s #insulin4all chapter, I’ve met countless patients who have struggled to afford their insulin.

and insulin pumps, which also make therapy more convenient, are already gaining in popularity. Novo Nordisk is investing heavily in another oral formulation: its next-generation GLP-1 analogue ...

The platform could provide an alternative to the "artificial pancreas" systems, which use glucose-sensing devices coupled with insulin pumps ... diabetes category Novo Nordisk is working on ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they ...

Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...